All posts

Marijuana companies are misleading investors, securities regulator finds

Growing pains are showing in Canada’s fledgling marijuana industry, according to the Canadian Securities Association (CSA), whose new report looks at the reporting practices of 70 public cannabis companies and finds that investors aren’t getting enough pertinent information regarding their financials.

The long-awaited end to cannabis prohibition is finally at hand as Canadians prepare themselves for legal weed as of this Wednesday. Industry experts are predicting an initial shortage in supply, with licensed growers currently scrambling to scale up production, while on the investor side, interest in Canada’s pot companies is at its peak and continues to push valuations higher, causing many to worry about a pot bubble ready to burst.

But the new report from the CSA, an umbrella group representing provincial and territorial securities regulators, effectively claims that the industry faces more problems than unmet quotas and sky-high valuations, arguing that accounting practices in the sector need to be clearer and more transparent, particularly surrounding the prospective value of the pot plants they’re growing.

Marijuana stocks soar but what is their true value?

“[International Financial Reporting Standards] require that growing cannabis plants be recorded at fair value and what our review found was that for licensed producers, their disclosure on income statements was weak around changes in fair value of those biological assets,” says John Hinze, director of corporate finance for the BC Securities Commission, in conversation with BNN Bloomberg.

“Keep in mind that accounting standards do provide choices and companies have to determine what accounting treatment is appropriate for them, and our role is to in part help to ensure that their disclosure is then sufficient,” says Hinze. “Specifically with respect to fair value changes, what we would say is a better disclosure practice would be to provide more information on the face of the income statement, for example, splitting out the components of those fair value changes, which would provide more information to investors so that they can more easily compare between cannabis issuers.”

The CSA has already had to deal with the thorny issue of Canadian pot companies that have interests in the United States, where cannabis is still a Schedule 1 narcotic at the federal level. Last year, it decided that companies should be allowed to go public as long as they clearly and fully describe both the nature of their US interests and how they plan to stay in compliance with US laws on a state-by-state basis.

Hinze says the new report found problems with a full 95 per cent of Canadian cannabis companies’ reporting yet that in no instances was there indication of deliberate attempts to mislead investors, which he says is a positive.

“It’s important for investors to have comparable financial information so that they can make informed choices,” Hinze says. “For investors who are in the cannabis industry, they should be aware that accounting policy provides for licensed producers to make choices around their accounting treatments and, of course, that could mean that their financial statements might look very different then their competitor.”

“Cannabis is a relatively young and rapidly changing industry and it’s not unusual for disclosure practice to vary more in a less mature industry like cannabis or blockchain and cryptocurrency versus more mature industries like mining or real estate,” he says.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

2 days ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

2 days ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

2 days ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

2 days ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

3 days ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

3 days ago